company background image
GLTO

Galecto NasdaqGS:GLTO Stock Report

Last Price

US$1.45

Market Cap

US$37.1m

7D

-5.8%

1Y

-51.3%

Updated

27 Nov, 2022

Data

Company Financials +
GLTO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

GLTO Stock Overview

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases.

Galecto, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Galecto
Historical stock prices
Current Share PriceUS$1.45
52 Week HighUS$3.53
52 Week LowUS$1.17
Beta0.039
1 Month Change-23.28%
3 Month Change-40.33%
1 Year Change-51.34%
3 Year Changen/a
5 Year Changen/a
Change since IPO-90.33%

Recent News & Updates

Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer

Oct 19

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Oct 19
Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Recent updates

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Oct 19
Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Jun 30
We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

Mar 10
Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Nov 18
We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Jul 07
Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Mar 23
We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

Jan 29
Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

Shareholder Returns

GLTOUS BiotechsUS Market
7D-5.8%0.4%1.3%
1Y-51.3%-14.4%-18.5%

Return vs Industry: GLTO underperformed the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: GLTO underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is GLTO's price volatile compared to industry and market?
GLTO volatility
GLTO Average Weekly Movement16.2%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: GLTO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: GLTO's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201140Hans Schambyehttps://galecto.com

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company’s lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

Galecto, Inc. Fundamentals Summary

How do Galecto's earnings and revenue compare to its market cap?
GLTO fundamental statistics
Market CapUS$37.09m
Earnings (TTM)-US$60.96m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GLTO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$60.96m
Earnings-US$60.96m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.38
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GLTO perform over the long term?

See historical performance and comparison